癌症小鼠模型中的静脉血栓形成测定
January 5th, 2024
3.3K views
本文旨在提出一种优化的评估小鼠癌症模型中静脉血栓形成的方法，使用血管夹实现静脉结扎。优化可最大限度地减少血栓形成相关测量的变异性，并增强与人类癌症相关静脉血栓形成的相关性。
本研究旨在增强静脉血栓形成的啮齿动物模型，重点关注癌症相关血栓形成。它介绍了一种在同基因结肠癌异种移植小鼠模型中使用血管夹的精细手术技术，以提高一致性和可重复性，促进癌症相关血栓形成机制的理解和药物发现。尽管2012年在IVT狭窄模型中引入了减少血流模型，但在过去10年中，癌症相关血栓形成模型没有取得重大进展。
这就是这一努力的理由。在癌症相关血栓形成研究领域，目前的技术包括先进的成像技术，如扫描、电子显微图像、分子生物学工具，如免疫荧光染色、精密手术器械、数据分析软件和数据解释，以及动物福利。目前的实验挑战包括血凝块重量的可变性、高死亡率以及静脉血栓形成啮齿动物模型中较长的学习曲线。
此外，静脉血流方向和血栓形成机制与临床病例不同。我们的研究方案弥合了癌症相关血栓形成啮齿动物模型的空白。它引入了一种在异种移植模型中使用血管夹的新型手术技术，产生了更一致和可重复的血栓形成结果。
这增强了我们对转化研究中癌症相关血栓形成和药物发现的理解。
概览
本研究提升了静脉血栓形成的啮齿动物模型，特别是在癌症相关血栓形成方面。它在同基因结肠癌异种移植小鼠模型中引入了使用血管夹的精细手术技术，以提高一致性和可重复性。
关键研究组成部分
科学领域
- 神经科学
- 肿瘤学
- 血管生物学
背景
- 癌症相关血栓形成研究的当前技术包括先进的成像技术和分子生物学工具。
- 过去的模型，如下腔静脉狭窄模型，在过去十年中未见重大进展。
- 理解癌症相关血栓形成对药物发现和治疗干预至关重要。
- 动物福利考虑是研究方法论的组成部分。
研究目的
- 优化小鼠癌症模型中静脉血栓形成的评估。
- 最小化血栓形成相关测量的变异性。
- 提高研究结果对人类癌症相关静脉血栓形成的相关性。
使用的方法
- 使用血管夹进行静脉结扎的精细手术技术。
- 同基因结肠癌异种移植小鼠模型。
- 用于评估的先进成像技术。
- 用于结果解释的数据分析软件。
主要结果
- 提高了血栓形成测量的一致性和可重复性。
- 增强了对癌症相关血栓形成机制的理解。
- 对癌症治疗中的药物发现可能有重要意义。
- 验证了在手术程序中使用血管夹的方法。
结论
- 优化的方法提供了一个研究静脉血栓形成的可靠模型。
- 研究结果可能导致更好的癌症相关血栓形成治疗策略。
- 未来的研究可以在此方法基础上进一步探索癌症中的血栓形成。
常见问题
这项研究的意义是什么？
这项研究提供了一个评估静脉血栓形成的优化模型，这对理解癌症相关血栓形成具有相关性。
新的手术技术如何改善结果？
使用血管夹的精细手术技术增强了血栓形成测量的一致性和可重复性。
对药物发现有什么影响？
对癌症相关血栓形成机制的改进理解可以帮助开发靶向治疗。
为什么在这项研究中考虑动物福利？
动物福利对确保研究结果的伦理标准和有效性至关重要。
这项研究使用了哪些技术？
该研究利用先进的成像技术和分子生物学工具进行评估和分析。
这项研究与以往的模型有何关联？
这项研究在以往模型的基础上，通过解决癌症相关血栓形成研究缺乏重大进展的问题而进行。
Executive Industry Relevance
Reliable preclinical models of cancer-associated venous thrombosis are essential for translational drug discovery and mechanistic de-risking in oncology portfolios. This refined mouse model using vascular clips addresses variability and reproducibility challenges, enabling more predictive assessment of thrombosis mechanisms and therapeutic interventions. Enhanced model consistency supports confident target validation and risk-adjusted advancement decisions in early discovery and translational research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic interrogation of cancer-associated thrombosis pathways in vivo.
- Reduces biological ambiguity by providing reproducible thrombosis outcomes for hypothesis testing.
- Supports functional target validation by correlating clot formation with molecular markers.
- Facilitates portfolio triage by improving predictive confidence in thrombosis-related targets.
Screening & Assay Development
- Prepares validated animal models for downstream efficacy and mechanistic screening of antithrombotic agents.
- Improves assay standardization and reproducibility through consistent clot mass and surface area measurements.
- Enables quantitative outputs for comparative evaluation of candidate compounds.
- Supports scalable and reusable model systems for iterative screening workflows.
Translational & Preclinical Research
- Aligns preclinical thrombosis models with disease-relevant mechanisms observed in cancer patients.
- Provides continuity from discovery through preclinical validation by integrating imaging and molecular readouts.
- Enables risk-adjusted advancement of antithrombotic strategies based on robust in vivo data.
- Supports translational biomarker development through immunofluorescence and imaging correlation.
Pipeline & Workflow Integration
This refined thrombosis model fits within the early discovery to preclinical continuum, supporting both mechanistic studies and translational drug evaluation in cancer-associated thrombosis.
- Discovery Biology: Facilitates hypothesis testing and pathway clarification for thrombosis mechanisms in cancer models.
- Screening: Provides reproducible, quantitative clot measurements for assay readiness and compound evaluation.
- Analytics: Integrates imaging and immunofluorescence outputs for robust statistical comparison of experimental groups.
- Translational Research: Bridges discovery and preclinical validation by modeling clinically relevant thrombosis phenotypes.
- Enterprise Reuse: Establishes a standardized, reusable platform for ongoing thrombosis research and drug screening.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in thrombosis research.
- Operational Value: Enhances standardization, reproducibility, and scalability of preclinical thrombosis models.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by reducing late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of thrombosis-targeted therapies.
Implementation Considerations
- Requires surgical expertise in vascular clip placement and animal model handling.
- Needs access to advanced imaging and immunofluorescence analysis infrastructure.
- Demands cross-team standardization of surgical and analytical protocols for reproducibility.
- May require adaptation for different cancer types or thrombosis models as supported by the protocol.
- Limitations include model-specific mortality rates and learning curve for surgical refinements.
Biopharma FAQs
Why does null hypothesis testing matter for clot mass quantification?
Null hypothesis testing in clot mass quantification enables objective assessment of thrombosis differences between experimental and control groups, supporting robust target validation. This statistical rigor ensures that observed effects are not due to random variation, increasing confidence in mechanistic findings. Reliable hypothesis testing underpins go/no-go decisions in thrombosis-targeted drug discovery.
How does independent variable isolation improve vascular clip model outputs?
Isolating the surgical variable—vascular clip versus suture—clarifies its direct impact on clot formation and variability, strengthening mechanistic interpretation. This approach reduces confounding factors, enabling more accurate attribution of outcomes to the intervention. Such isolation is critical for pipeline integration and comparative evaluation of thrombosis models.
What do quantitative clot weight and surface area measurements enable?
Quantitative measurements of clot weight and luminal surface area provide reproducible, objective endpoints for comparing thrombosis severity across groups. These outputs support statistical analysis, facilitate cross-study comparisons, and enable reliable screening of candidate therapeutics. Quantitative data are essential for translational alignment and portfolio decision-making.
Why are replication requirements critical for cross-functional thrombosis studies?
Replication ensures that thrombosis outcomes are consistent and reproducible across experiments and teams, reducing biological and operational risk. This is vital for cross-functional collaboration, as standardized outputs enable integration of imaging, molecular, and pharmacological data. High replication supports enterprise-wide confidence in model-derived insights.
What statistical analysis capabilities are needed before implementing clot mass endpoints?
Robust statistical analysis—including variance assessment and group comparisons—is required to validate clot mass endpoints and ensure reproducibility. Teams must have access to appropriate data analysis software and expertise to interpret quantitative outputs. These capabilities are foundational for reliable model deployment and downstream decision-making.
